Trial Profile
Measurement of Gemcitabine Metabolites in Blood and Urine as Predictors of Response to GemX Bladder Radiotherapy.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 16 Oct 2020
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary)
- Indications Bladder cancer
- Focus Therapeutic Use
- Acronyms Gemtrans
- 13 Oct 2020 Status changed from active, no longer recruiting to completed.
- 04 Jan 2018 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last verifiedJan 2016 ).
- 26 Jan 2016 Planned End Date changed from 1 Dec 2017 to 1 Jan 2018, as reported by ClinicalTrials.gov.